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tephen Sidney, MD, MPH,* Joan M. Fair, ANP, PHD,‡ Thomas Quertermous, MD,§
ark A. Hlatky, MD,§ Stephen P. Fortmann, MD‡
akland, San Francisco, and Stanford, California
OBJECTIVES We sought to examine the association between the metabolic syndrome (MetS) (defined both
by the 2001 National Cholesterol Educational Program Adult Treatment Panel III
[ATP-III] definition and the American Heart Association/National Heart, Lung and Blood
Institute [AHA/NHLBI] revision incorporating the lower threshold for impaired fasting
glucose [IFG]) and early-onset coronary artery disease (CAD).
BACKGROUND The impact of MetS on premature CAD has not been studied extensively. Lowering the
threshold to define the IFG component (from 110 to 100 mg/dl) and the value of the
syndrome as a whole versus its individual components are subjects of intense debate.
METHODS We performed a case-control study with 393 early-onset CAD subjects (acute myocardial infarction,
angina with50% stenosis, or coronary revascularization) in men under age 46 years or women under
age 56 years and 393 control subjects individually matched for gender, age, and race/ethnicity.
RESULTS By conditional logistic regression, presence of ATP-III MetS without diabetes (adjusted odds
ratio [adj-OR] 4.9; 95% confidence interval [CI] 3.4 to 8.0) and with diabetes (adj-OR 8.0,
95% CI 4.39 to 14.6) was a strong independent determinant of early-onset CAD. Using the
AHA/NHLBI revision, these ORs became slightly stronger. However, neither definition of
MetS remained significantly associated with early-onset CAD in multivariate models
adjusting for individual components.
CONCLUSIONS The presence of MetS imparts a high risk of early-onset clinical CAD, but the prognostic
information associated with the syndrome is not greater than the sum of its parts. (J Am
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.03.070Coll Cardiol 2006;48:1800–7) © 2006 by the American College of Cardiology Foundation
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pn 2001, the National Cholesterol Educational Program Adult
reatment Panel III (NCEP-ATP-III) defined the metabolic
yndrome (MetS) as a clustering of 3 or more vascular risk factors,
ncluding abdominal obesity, high triglycerides, low high-density
ipoprotein cholesterol, high blood pressure, and high fasting
lucose (1). Subsequent studies have shown that the MetS defined
sing the ATP-III imparts an increased risk of type 2 diabetes
ellitus as well as clinical (2–9) and subclinical (10–13) coronary
rtery disease (CAD) in older populations. Because the prevalence
f MetS is increasing alarmingly among adolescents and young
dults because of adverse physical activity and dietary patterns (14),
t is important to quantify its relation with clinical CAD occurring
arly in life.
A recent American Heart Association/National Heart,
ung, and Blood Institute (AHA/NHLBI) report (15)
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ung, and Blood Institute.s
Manuscript received December 19, 2005; revised manuscript received February 10,
006, accepted March 16, 2006.ecommends lowering the threshold for impaired fasting
lucose (IFG) from 110 to 100 mg/dl, following the
ecently modified American Diabetes Association (ADA)
riteria for IFG (16). However, the impact of changing the
lucose threshold for IFG has not been rigorously evaluated
nd has been called into question because it could expand
he population with MetS by about 20% (17).
Besides the IFG controversy, the clinical utility of the
etS above and beyond its individual components remains
ncertain and has led to a critical appraisal of the syndrome
18,19). The present study was undertaken to: 1) evaluate
he association between MetS (defined using both the
TP-III criteria and the new AHA/NHLBI criteria) and
arly-onset CAD; and 2) ascertain whether the MetS
defined with both criteria) adds beyond the contribution of
he component risk factors.
ETHODS
tudy population and design. The ADVANCE (Athero-
clerotic Disease, Vascular Function, and Genetic Epidemiology)
tudy is a case-control investigation of genetic and nongenetic
eterminants of CAD and mode of CAD presentation. All study
articipants have been identified and recruited from the member-
hip of Kaiser Permanente of Northern California (KPNC), a
l
B
o
T
I
w
a
r
D
t
e
a
c
C
t
(
3
c
e
p
a
o
e
e
a
p
o
A
p
(
i
C
p
l
h
a
a
A
1
t
o
4
o
3
i
5
b
l
p
W
c
d
F
c
C
1801JACC Vol. 48, No. 9, 2006 Iribarren et al.
November 7, 2006:1800–7 Metabolic Syndrome and Premature Coronary Diseasearge integrated health care delivery system in the San Francisco
ay area and surrounding counties.
As part of the overall design, the study included “early-
nset” CAD subjects and age-matched control subjects.
he definition of early-onset CAD is presented in Figure 1.
n short, it included men aged 18 through 45 years and
omen aged 18 through 55 years who were hospitalized for
cute myocardial infarction (AMI), angina, or a coronary
evascularization procedure between January 1, 1999, and
ecember 12, 2003. Because the case subjects had to survive
he index event and up to the clinic visit, we were unable to
nroll out-of-hospital sudden cardiac death or fatal cardiac
rrest in the hospital. The combination of primary discharge
ode 410.x of the ninth revision of the International
lassification of Diseases plus evidence of peak cardiac
roponin I of 4 ng/dl or combination of creatine kinase
CK)-MB fraction of 5.6 ng/ml and CK-MB percentage of
.3 during hospital admission has 96% specificity using
igure 1. Early-onset coronary artery disease (CAD) definition criteria in
Abbreviations and Acronyms
ADA  American Diabetes Association
ADVANCE  Atherosclerotic Disease, Vascular
Function, and Genetic Epidemiology
AHA/NHLBI  American Heart Association/
National Heart, Lung, and Blood
Institute
CAD  coronary artery disease
CARDIA  Coronary Artery Risk Development
in Young Adults
HOMA-IR  homeostasis model assessment of
insulin resistance
IFG  impaired fasting glucose
KPNC  Kaiser Permanente of Northern
California
MetS  metabolic syndrome
NCEP-ATP-III  National Cholesterol Educational
Program Adult Treatment Panel IIIreatine kinase-MB fraction; CPT  current procedural terminology; EKG
lassification of Diseases; MD  metabolic syndrome; PCI  percutaneous cohart review as the “gold standard” (4). The sequence of
xclusions for medical or residential reasons, the number of
articipant refusals before or after the screening interview,
nd the number of case subjects excluded after completion
f the clinic visit are detailed in Figure 2. Briefly, after initial
lectronic exclusions, there were 1,820 eligible patients with
arly-onset CAD; 1,418 (78%) were contacted by recruiters,
nd, of those, 566 (40%) were deemed eligible and agreed to
articipate. Clinic visits ended when the target recruitment
f 500 case subjects was reached.
The selection of young control subjects was done in 2 steps.
bout two-thirds of the control subjects (n 479; 65%) were
articipants in the year 15 examination of the CARDIA
Coronary Artery Risk Development in Young Adults) study
n 2000 to 2001 at the Oakland CARDIA clinic. These
ARDIA participants were not re-examined; rather, we used
reviously collected DNA and risk factor data. CARDIA is a
ongitudinal study funded by the NHLBI to examine coronary
eart disease (CHD) risk factors in black and white young
dults (20). The CARDIA subjects were first enrolled in 1985
nd 1986 when they were between 18 and 30 years old.
mong the 1,005 CARDIA Oakland participants at the year
5 visit, 4 were excluded owing to history of CAD, 1 for being
ransgender, and 189 for having insufficient DNA stored. Out
f these 811, we randomly selected (in gender and race strata)
79 subjects as control subjects for young case subjects of white
r black race. The remaining young control subjects (n 264;
5%) were recruited de novo from the KPNC membership. An
nitial pool of KPNC members was assembled consisting of
7,988 men between the ages of 18 and 45 years and women
etween the ages of 18 and 55 years (as of June 30, 2003) who
ived in the San Francisco Bay area and had continuous health
lan membership between January 1998 and June 30, 2003.
e then excluded subjects with a history of diagnosed
ardiovascular disease, systemic cancer, end-stage renal
isease, cirrhosis, dementia, and bone marrow or organ
ADVANCE Study. CABG  coronary artery bypass graft; CK-MB the
 electrocardiogram; ICD-9  ninth revision of the International
ronary intervention.
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Metabolic Syndrome and Premature Coronary Disease November 7, 2006:1800–7ransplants, as well as those who previously requested not
o be contacted for research studies or who did not have
regular primary care physician, leaving an eligible pool
f 50,507. Age, gender, and race strata were created, and
e selectively recruited persons with the aim of frequency
atching to the young case subjects on age, gender, and
ace/ethnicity.
We then excluded 31 case subjects and 82 control subjects
n whom 1 or more components of the metabolic syndrome
ere missing or values for glucose or triglycerides were
onfasting, leaving 469 case subjects and 661 control
ubjects. To ensure optimal case-control balance by gender
nd race (non-Hispanic white, non-Hispanic black, His-
anic/Latino, Asian/Pacific Islander, other, or mixed), we
ssembled a subset of case subjects and control subjects
sing 1:1 matching on gender and race. This resulted in 393
igure 2. Schematic representation of the recruitment process for early-on
are provider. *Numbers do not add up because electronic exclusions are natched pairs. rRace/ethnicity was based on the subjects’ self-identification and
y grandparents’ country of origin. Educational attainment, ciga-
ette smoking status, and average consumption of beer, wine,
nd liquor over the last 12 months were collected by
elf-administered questionnaires. Height, weight, and waist
ircumference were measured at the clinic visit by certified
ersonnel using standard instruments and protocols. Before
he measurement of blood pressure, subjects were fasting
nd instructed to avoid heavy physical activity, smoking, and
affeine. Before measuring blood pressure, subjects were
eated for 5 min with feet flat on the floor and told to relax
nd to avoid talking. The blood pressure cuff size was based
n the individual’s arm circumference, and all readings were
aken in the right arm by an automated digital vital signs
onitor from Welch Allyn (Skaneateles Falls, New York),
odel 5200. A total of 3 readings were taken with a 1-min
ronary artery disease subjects in the ADVANCE study. PCP  primary
utually exclusive.set coest period between assessments, and the average of second
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November 7, 2006:1800–7 Metabolic Syndrome and Premature Coronary Diseasend third readings were used in analysis. Serum lipid levels
low-density lipoprotein cholesterol, high-density lipopro-
ein [HDL] cholesterol, and triglycerides) were measured in
asting serum at the Stanford Hospital and Clinics Labo-
atory, which is certified by the Centers for Disease Control/
HLBI Lipid Standardization Program. Fasting blood
lucose was determined with a hexokinase reagent kit (Wash-
ngton University, Saint Louis, Missouri). Diabetes mellitus
as defined as self-report of a physician diagnosis of diabetes
ellitus, use of insulin, oral hypoglycemic, or insulin sensitiz-
ng agents, or fasting blood glucose 126 mg/dl at the study
isit. Plasma C-reactive protein (CRP) was measured using
n immunoturbidimetric assay on the Hitachi 917 analyzer
Roche Diagnostics, Indianapolis, Indiana), using reagents
nd calibrators from Denka Seiken (Niigata, Japan). Data
ollection methods for the CARDIA study year 15 exami-
ation have been described elsewhere (21). Whenever pos-
ible (i.e., educational attainment, personal medical history,
moking, alcohol consumption, anthropometry), the survey
nstruments and the clinic procedures used for the case
ubjects and the non-CARDIA control subjects were the
ame as those used in the CARDIA study.
The presence of MetS was determined using 2 definitions: the
001 NCEP-ATP-III definition (1) (waist circumference 102
m in men or 88 cm in women, fasting triglycerides 150
g/dl, HDL-cholesterol 40 mg/dl in men or 50 mg/dl in
omen, hypertension defined as blood pressure130/85 mm Hg
r use of blood pressure medication, and IFG 110 mg/dl) and
he revised AHA/NHLBI definition (15) incorporating the lower
hreshold for IFG (100 mg/dl). Fasting blood glucose of126
g/dl was considered diagnostic of diabetes. We then categorized
ase subjects and control subjects (according to both ATP-III and
HA/NHLBI criteria) into the following mutually exclusive
roups: MetS without diabetes, diabetes without MetS, diabetes
ith MetS, and neither of these conditions. We did not imple-
ent the World Health Organization criteria (22) for MetS
ecause it requires oral glucose tolerance testing, which was not
erformed in our study subjects.
tatistical analysis. All analyses were conducted using
AS statistical software version 9 (SAS Institute, Cary,
orth Carolina). Univariate case-control comparisons were
erformed using appropriate tests for paired data, including
he paired t test for normally distributed continuous variables,
he Wilcoxon matched pairs signed rank test for non-normally
istributed continuous variables, the McNemar test for 2  2
ategoric variables and the generalized Mantel-Haenzel test for
 n categoric variables (where n 2). For assessing
ormality, we relied on graphic methods, including box
lots and normal probability plots. Conditional logistic
egression was then applied to quantify the relative odds of
arly-onset CAD associated with MetS without diabetes,
ith diabetes without MetS, and with diabetes with MetS
elative to having neither of these conditions. Two sequen-
ial models were fitted: first a model with no adjustment for
ovariates (gender and race are adjusted for by design), and
econd a model adjusting for covariates external to MetS cncluding age, educational attainment, body mass index, any
se of alcohol consumption in the past year, and cigarette
moking status. Next, we assessed the strength of associa-
ion of each of the 5 individual components categorically
efined (i.e., all components included in the same model)
ith early-onset CAD. To ascertain the prognostic impor-
ance of the MetS above and beyond its components, we
hen added a dichotomous term representing MetS to the
odel already including the 5 categoric components. Be-
ause the cut points to define the components are somewhat
rbitrary, the same analysis was repeated entering the
ndividual components as continuous variables, divided by
heir gender-specific standard deviation.
ESULTS
verall, 59% of early-onset CAD subjects (n 230) were acute
yocardial infarction, 26% (n  101) had a revascularization
rocedure, and 16% (n  62) had a diagnoses of angina with
50% stenosis on coronary angiography. By gender, these per-
entages were 60%, 29%, and 11% in men and 57%, 24%, and
9% in women. The baseline characteristics of case and control
ubjects are presented in Table 1. Mean age was 46 years in
arly-onset CAD subjects and 45 years in control subjects;
ender (61% female) and the race/ethnicity distribution
61% white) were identical in case subjects and control
ubjects by design. Compared with control subjects, case
ubjects had lower education attainment and were more
ikely to be former or current smokers and less likely to
eport any alcohol use in the past year. By beverage type,
ase subjects who reported alcohol use in the past year
compared with control subjects who also reported alcohol
se in the past year) tended to consume less wine, but no
ignificant differences were noted for beer or liquor. Also
ompared with control subjects, case subjects had higher
ystolic blood pressure, higher prevalence of hypertension,
ower HDL cholesterol, and higher levels of fasting triglyc-
rides, CRP, glucose, insulin, and homeostasis model as-
essment of insulin resistance. Body mass index and waist
ircumference were greater among case subjects, with 54%
f case subjects being obese compared with 27% of control
ubjects. The LDL cholesterol was lower in case subjects
han in control subjects, owing to the fact that a substan-
ially higher proportion of case subjects (89% vs. 6%) were
sing lipid-lowering medication. By both criteria, the pres-
nce of MetS without diabetes, diabetes without MetS, and
iabetes with MetS was significantly higher in case subjects
han in control subjects. By using the AHA/NHLBI
riteria, the prevalence of MetS without diabetes increased
o 32% from 28% (i.e., by 14%) among case subjects and to
1% from 10% (i.e., by 1%) among control subjects. In turn,
dopting the AHA/NHLBI criteria resulted in very little
hange in the prevalence of MetS with diabetes (to 26%
rom 25%, a 4% increase) among case subjects and no
hange (5%) among control subjects.
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Metabolic Syndrome and Premature Coronary Disease November 7, 2006:1800–7The prevalence of the individual components of MetS is
hown in Table 2. Hypertension followed by low HDL
holesterol and large waist circumference were the most com-
on components among case subjects; low HDL cholesterol
nd hypertension were also the most common components
mong control subjects. Whereas 31% of case subjects and 8%
f control subjects had IFG by ATP-III criteria, 49% and 15%,
espectively, did by AHA/NHLBI criteria. The case/control
revalence ratio was highest for ATP-III fasting glucose (3.9)
nd lowest for high triglycerides (1.9).
In conditional logistic regression adjusting for educa-
able 1. Characteristics of Early-Onset Coronary Artery Disease
Variable
Early-Onset CA
(n  39
ge, yrs 45.8 
omen 239 (61%
hite race 238 (61%
lack race 43 (11%
ispanic/Latino race 42 (11%
sian race 35 (9%
ther/mixed race 35 (9%
ducation level
Less than high school 30 (8%
High school graduate or some college 258 (66%
College graduate 82 (21%
Post-graduate degree 21 (5%
Unknown 2 (0.5
Current cigarette smoking* 95 (24%
Former cigarette smoking 139 (35%
Never cigarette smoking 156 (40%
Unknown smoking status 3 (0.8
se of any alcohol in past 12 months 267 (68%
Beer, drinks/week among drinkers 1.3 
Wine, drinks/week among drinkers 1.5 
Liquor, drinks/week among drinkers 0.8 
ystolic blood pressure 118.6 
iastolic blood pressure 73.1 
ypertension 308 (78%
TP-III MetS
Neither MetS nor diabetes 153 (39%
MetS without diabetes 109 (28%
Diabetes without MetS 31 (8%
MetS with diabetes 100 (25%
HA/NHLBI MetS
Neither MetS nor diabetes 136 (35%
MetS without diabetes 126 (32%
Diabetes without MetS 27 (7%
MetS with diabetes 104 (26%
DL cholesterol, mg/dl 45.0 
DL cholesterol, mg/dl 100.4 
riglycerides, mg/dl¶ 128 
-reactive protein, mg/dl¶ 2.36 
asting glucose, mg/dl¶ 99.0 
asting insulin, iU/ml¶ 12.4 
OMA-IR, mol  iU/l¶ 3.24 
se of cholesterol-lowering agents 351 (89%
ody mass index, kg/m2 31.4 
aist circumference, cm 96.7 
or non-normally distributed variables, median  interquartile range is shown. *As
AHA  American Heart Association; ATP-III  Adult Treatment Panel III; H
esistance; LDL  low-density lipoprotein; MetS  metabolic syndrome; NHLBI ional attainment, cigarette smoking, alcohol consumption, wnd body mass index (with having neither MetS nor
iabetes as the reference level) (Table 3), the odds ratios
95% confidence intervals [CI]) for early-onset CAD asso-
iated with MetS without diabetes, diabetes without MetS,
nd MetS with diabetes, respectively, were 4.9 (95% CI 3.4
o 8.0), 7.2 (95% CI 3.2 to 16), and 8.0 (95% CI 4.4 to 14.6)
sing the ATP-III criteria and 5.7 (95% CI 3.5 to 9.2), 6.3
95% CI 2.8 to 14.3), and 10.5 (95% CI 5.7 to 19.2) using
he AHA/NHLBI criteria. Further adjustment for CRP
ttenuated only slightly the odds ratio estimates (data not
hown). We performed a subset analysis to determine
D) Cases and Controls
bjects Control Subjects
(n  393) p Value
45.2  5.6 0.06
239 (61%) Matching factor
238 (61%) Matching factor
43 (11%)
42 (11%)
35 (9%)
35 (9%)
13 (3%) 0.0001
144 (37%)
133 (34%)
103 (26%)
0 (0%)
52 (13%) 0.0001
82 (21%)
258 (65%)
1 (0.3%)
335 (85%) 0.0001
1.9  7.5 0.29
2.4  4.4 0.05
0.6  1.6 0.92
114.5  14.6 0.0004
74.4  10.0 0.05
115 (29%) 0.0001
0.0001
325 (83%)
38 (10%)
10 (3%)
20 (5%)
0.0001
318 (81%)
45 (11%)
10 (3%)
20 (5%)
53.7  14.8 0.0001
119.1  31.6 0.0001
93  71 0.0001
0.94  2.3 0.001
88.0  15 0.0001
9.0  8.3 0.0001
1.94  1.8 0.0001
25 (6%) 0.0001
27.8  6.7 0.0001
87.2  14.8 0.0001
ex date.
high-density lipoprotein; HOMA-IR  homeostasis model assessment of insulin
ional Heart, Lung, and Blood Institute.(CA
D Su
3)
6.5
)
)
)
)
)
)
)
)
)
)
%)
)
)
)
%)
)
3.5
3.1
2.5
18.6
10.5
)
)
)
)
)
)
)
)
)
13.2
28.7
115
4.3
29
13.3
4.5
)
7.0
16.0
of indhether the associations of interest were similar when
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November 7, 2006:1800–7 Metabolic Syndrome and Premature Coronary Diseaseestricting the analysis to AMI (n  230) and correspond-
ng matched control subjects (n 230). Compared with the
composite case” definition, there was a weakening of the
ffect of MetS with diabetes (particularly when using the
TP-III MetS definition), but the AMI estimates were all
ell within the 95% CI of the composite case definition
stimates (data not shown).
Next, we assessed the prognostic value of MetS above and
eyond its individual components. In conditional logistic
egression adjusting for educational attainment, cigarette
moking, alcohol consumption, body mass index, and dia-
etes, MetS by the ATP-III criteria was associated with
.70 (95% CI 2.41 to 5.68) increased odds of early-onset
AD; MetS by the AHA/NHLBI criteria was associated
ith 4.57 (95% CI 2.98 to 7.01) increased odds of early-
nset CAD. In a model containing the previously men-
ioned external covariates plus the 5 components defined
ccording to the ATP-III definition (Table 4), low HDL
holesterol, hypertension, and IFG were significantly asso-
iated with early-onset CAD, and the strongest association
y far was with hypertension. Similar overall results were
btained in the model with AHA/NHLBI MetS compo-
ents, although the association with IFG was stronger using
he AHA/NHLBI threshold of 100 to 125 mg/dl (adjusted
dds ratio 4.1) than the ATP-III threshold of 110 to 125
g/dl (adjusted odds ratio 2.7). After all 5 components plus
xternal variables and diabetes were in the model, MetS was
o longer significantly associated with early-onset CAD,
nd this was true regardless of the definition used.
We also performed supplementary analysis to address the
ssue of whether MetS without diabetes, diabetes without
etS, or diabetes with MetS is still associated with CAD after
djustment for the MetS components as categoric variables.
fter adjusting for the components, the odds ratios were 1.63
95% CI 0.55 to 4.82) for MetS without diabetes, 9.02 (95%
Table 2. Prevalence of Metabolic Syndrome C
Metabolic Syndrome Component
Waist circumference 102 cm (men); 88 cm (women)
Triglycerides 150 mg/dl
HDL cholesterol 40 mg/dl (men); 50 mg/dl (wo
Hypertension
ATP-III fasting glucose 110–125 mg/dl
AHA/NHLBI fasting glucose 100–125 mg/dl
Abbreviations as in Table 1.
able 3. Adjusted* Association Between Joint Categories of
etabolic Syndrome (MetS) and Diabetes and Early-Onset
oronary Artery Disease
ATP-III MetS AHA/NHLBI MetS
etS without diabetes 4.95 (3.4–8.05) 5.70 (3.55–9.16)
iabetes without MetS 7.21 (3.24–16.0) 6.31 (2.78–14.3)
etS with diabetes 8.00 (4.39–14.6) 10.5 (5.70–19.2)
Adjusted for age, educational attainment, cigarette smoking, alcohol consumption,a
nd body mass index.
Abbreviations as in Table 1.I 2.50 to 32.49) for diabetes without MetS, and 2.02 (95%
I 0.51 to 8.08) for MetS with diabetes when using the
TP-III MetS definition. Corresponding estimates using the
HA/NHLBI MetS definition were 1.38 (95% CI 0.64 to
.97) for MetS without diabetes, 3.75 (95% CI 1.48 to 9.51)
or diabetes without MetS, and 1.65 (95% CI 0.63 to 4.33) for
etS with diabetes.
Because the use of categoric variables has been disputed
n the basis that risk is really a progressive function, we
epeated the analysis of components using continuous vari-
bles for waist circumference, triglycerides, HDL choles-
erol, and fasting glucose. In agreement with the categoric
nalysis, the effect of MetS (both by ATP-III and by
HA/NHLBI criteria) was greatly attenuated and lost
tatistical significance after adjustment for the individual
omponents (Table 5).
ISCUSSION
he prevalence of MetS is increasing at an alarming rate in
oung people (14). However, very few studies have quanti-
ed the impact of MetS on CAD occurring early in life. We
lso focused on 2 critical issues: 1) what are the repercus-
ions of adopting the newly proposed threshold for IFG
100 to 125 mg/dl) in terms of the prevalence of the
yndrome and its association with early-onset CAD; and 2)
s MetS associated or not with greater risk of atherosclerotic
ardiovascular disease more so than any of its individual
omponents? It has been argued that the concept of syn-
rome implies that the risk associated with having the
yndrome ought to be greater than the sum of its parts, and
hat all the factors should have a common underlying
hysiology which is responsible for their clustering (18).
In the present study, after adjusting for external risk factors, the
resence of the MetS by ATP-III criteria in the absence of
iabetes conferred an almost 5-fold increase in the odds of
arly-onset CAD; combined with diabetes, the odds ratio was 8.
he AHA/NHLBI definition resulted in a slightly better predic-
ion of outcome: the odds ratios were almost 6 and 10, respec-
ively, for MetS without diabetes and with diabetes. However, in
ultivariate analysis, MetS (regardless of the definition used)
onveyed no additional predictive information beyond its compo-
ents, casting doubt on the clinical utility of MetS. A logical
nterpretation of this finding is that clinicians would be better off
nents by Case-Control Status
Cases
(n  393)
Controls
(n  393)
Prevalence
Ratio
55% 28% 2.0
39% 21% 1.9
59% 30% 2.0
78% 29% 2.7
31% 8% 3.9
49% 15% 3.3ompo
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ondition like MetS, even if it does not provide incremental value
ver its components, may better motivate physicians to treat the
ondition and its accompanying risk factors.
Previous investigators have reached similar conclusions. For
xample, blood pressure, HDL cholesterol, and diabetes, but not
resence of MetS, were significant multivariate predictors of
revalent CHD in a recent analysis of the Third National Health
nd Nutrition Examination Survey (23). In the Caerphilly and
peedwell population studies, the excess of ischemic heart disease
isk associated with MetS was no greater than can be explained by
ndividual effects of the defining variables in a multiple logistic
odel (24).
We found that the components of MetS more strongly
ssociated with early-onset CAD were hypertension, low
DL cholesterol, and IFG. Notably, IFG defined by the
ower AHA/NHLBI threshold was more strongly associ-
ted with the outcome than IFG defined by the ATP-III
riteria. Waist circumference and triglycerides were not
ndependently related to early-onset CAD. This is most
ikely due to the fact that the effect of visceral adiposity is
argely mediated by the other factors, and by the high
orrelation between triglycerides and HDL cholesterol
Spearman r0.53 combining case and control subjects).
To our knowledge, this is the first study describing the
ssociation between MetS and early-onset clinical CAD using
oncurrent age-, gender-, and race-matched control subjects.
able 4. Adjusted* Odds Ratios (95% Confidence Intervals) of E
efined Components of the Metabolic Syndrome (MetS) and W
Component ATP-III MetS
AHA/
M
aist circ. 102 (men), 88 cm (women) 1.29 (0.74–2.26) 1.15 (0.
riglycerides 150 mg/dl 0.78 (0.50–1.23) 0.81 (0.
DL cholesterol 40 (men),
50 mg/dl (women)
2.91 (1.96–4.31) 3.09 (2.
ypertension 7.26 (4.92–10.70) 7.27 (4.
asting glucose 110–125 mg/dl 2.71 (1.60–4.57)
asting glucose 100–125 mg/dl 4.06 (2.
TP-III MetS
HA/NHLBI MetS
All components entered into the same model and adjusted for age, educational atta
circ.  circumference; other abbreviations as in Table 1.
Table 5. Adjusted* Odds Ratios (95% Confide
Disease Associated With Continuously Define
(MetS) and With the Syndrome Above and B
Component
Compone
Only
Waist circumference, per 1 SD 0.96 (0.82–
Triglycerides, per 1 SD 1.01 (0.79–
HDL cholesterol, per 1 SD 0.63 (0.52–
Hypertension 6.70 (4.58–
Fasting glucose, per 1 SD 1.94 (1.43–
ATP-III MetS
AHA/NHLBI MetS
SD waist circumference of 13 cm in men, 17 cm in women; t
11 mg/dl in men, 15 mg/dl in women; glucose  42 mg/dl in
model and adjusted for age, educational attainment, cigarette smok
Abbreviations as in Table 1.n earlier study in Turkey recruited 582 consecutive patients
496 men, 86 women) with newly diagnosed premature CAD
age45 years), but did not include control subjects (25). The
verall prevalence of MetS using ATP-III criteria (but includ-
ng diabetics) in that study was 37%; the prevalence of MetS
ithout diabetes was not reported.
Previous studies have shown that older individuals with MetS
re at 2- to 3-fold increased risk of cardiovascular morbidity and
ortality (4,5,7,23,26). The demonstration here of an even stron-
er effect of the presence of MetS without diabetes on early-onset
AD constitutes important new evidence for primary and sec-
ndary prevention of CAD in young adulthood.
Based on the strength of associations observed for the individ-
al components and the fact that the association of the MetS with
arly-onset CAD was greatly attenuated and no longer significant
fter adjustment for its components, our data support the view
hat more intensive efforts should be directed toward prevention
nd management of the individual risk factors (particularly hyper-
ension, low HDL cholesterol, and IFG) than to “diagnosing” the
yndrome. From the standpoint of primary prevention, interven-
ions designed to increase exercise and achieve weight loss have
een shown to effectively reduce these risk factors (27). In
ddition, drug treatment for hypertension is well established, but
efinitive randomized clinical trial data supporting the use of drugs
imed at increasing HDL cholesterol levels independent of low-
ring LDL cholesterol levels are still needed.
Onset Coronary Artery Disease Associated With Categorically
e Syndrome Above and Beyond Its Components
BI ATP-III Components 
ATP-III MetS
AHA/NHLBI Components 
AHA/NHLBI MetS
04) 1.26 (0.69–2.28) 1.10 (0.59–2.05)
28) 0.75 (0.44–1.28) 0.77 (0.46–1.31)
63) 4.82 (1.80–4.42) 2.97 (1.87–4.69)
.83) 7.10 (4.67–10.79) 7.06 (4.60–10.82)
2.63 (1.50–4.62)
38) 3.91 (2.38–6.41)
1.11 (0.53–2.31)
1.15 (0.55–2.41)
t, cigarette smoking, alcohol consumption, and body mass index.
ntervals) of Early-Onset Coronary Artery
mponents of the Metabolic Syndrome
Its Components
Component 
ATP-III MetS
Component 
AHA/NHLBI
0.95 (0.80–1.12) 0.92 (0.78–1.09)
0.98 (0.76–1.26) 0.94 (0.74–1.20)
0.65 (0.52–0.81) 0.68 (0.55–0.85)
6.40 (4.30–9.52) 5.96 (4.0–8.86)
1.90 (1.39–2.58) 1.83 (1.35–2.48)
1.22 (0.71–2.12)
1.66 (0.98–2.82)
rides 121 mg/dl in men, 107 in women; HDL cholesterol
49 mg/dl in women. *All components entered into the samearly-
ith th
NHL
etS
65–2.
52–1.
07–4.
88–10
59–6.nce I
d Co
eyond
nt
1.13)
1.28)
0.78)
9.77)
2.63)
riglyce
men,ing, alcohol consumption, and body mass index.
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November 7, 2006:1800–7 Metabolic Syndrome and Premature Coronary Diseasetudy limitations. First, our case definition excluded fatal
AD, because subjects were identified and invited to attend
clinic visit after being discharged alive from the hospital.
hus, we could not ascertain whether MetS or its compo-
ents are more or less relevant for fatal versus nonfatal
AD. Second, the majority of case subjects (90%) re-
eived treatment for dyslipidemia (vs. 6% of control sub-
ects) and therefore had therapeutically lowered LDL cho-
esterol. Consequently, we were unable to statistically adjust
or lipid-lowering medication and LDL cholesterol as
xternal variables to the syndrome.
Although triglycerides remained significantly higher in early-
nset CAD subjects compared with control subjects, the high
revalence of lipid-lowering use may have contributed also to
eakening the association of triglycerides with early-onset CAD
n our study. Finally, participants were all insured (CARDIA
ontrol subjects also were recruited from KPNC), and therefore
ur findings may not apply to uninsured populations.
The strengths of the study include the availability of a
nique large set of very well characterized case subjects with
arly-onset clinical CAD, which is a relatively rare event
hat requires very large source populations. We also re-
ruited young adults free of cardiovascular disease for ideally
atched control subjects. Second, our sample was ethnically
iverse and recruited directly from the communities covered
y a large integrated health care delivery system, which
ncreases the generalizability of the findings.
onclusions. The present results provide new evidence that
he presence of MetS without and with diabetes is a strong
ndependent determinant of early-onset CAD. Moreover, the
HA/NHLBI revision to the ATP-III criteria appeared to
etter predict outcome. However, the results of our analysis
uggest that MetS does not constitute a syndrome that is more
rognostic than the sum of its parts.
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